Clinical trials
Adverse Event clinical trials
Below are recruiting adverse event clinical trials, each written for real people, not researchers. We’re tracking 191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07276997RecruitingPhase 2
Study of Icalcaprant for major depressive disorder
This trial tests an oral medication called icalcaprant for adults with major depressive disorder (MDD). It aims to see if the drug can reduce depression symptoms and what side effects may occur.
Dothan, AlabamaAges 18–65 - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT01258231Recruiting
Genetic test to predict risks after heart surgery
This study looks for genetic (DNA) clues that may help predict side effects or complications after heart surgery. If you join, your genome information may be used to understand who is at higher risk and why.
Boston, MassachusettsAges 20–90 - NCT02315599Enrolling by invitation
Follow-up for delayed side effects after gene-cell therapy
This study checks people for delayed side effects after receiving gene-based cell therapy from the NIH. It helps doctors learn what problems may happen later and how to monitor them safely.
Bethesda, MarylandAges 1–99 - NCT07409246RecruitingPhase 1
Study of ABBV-438 for multiple myeloma patients
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Duarte, CaliforniaAges 18 years+ - NCT07514260RecruitingPhase 1
Safety study of ABBV-295 injections in Japanese adults with overweight
This is an early-stage safety study testing a new injectable medication (ABBV-295) in healthy Japanese adults who are overweight or have obesity. The study measures how well the body tolerates the drug and how it moves through the body.
Anaheim, CaliforniaAges 18–65 - NCT07604558RecruitingPhase 1
Safety study of bretisilocin injection in healthy adults
This is an early-stage safety study testing how a new injection called bretisilocin moves through your body and what side effects it may cause. Researchers are enrolling healthy adults from different ethnic backgrounds to understand if the drug is safe.
Los Alamitos, CaliforniaAges 18–65 - NCT07607587RecruitingPhase 1
Testing a new weight-loss drug for people who couldn't tolerate GLP-1 shots
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
Walnut Creek, CaliforniaAges 18 years+ - NCT07644897RecruitingPhase 2
Thymosin Alpha 1 Plus Anti-PD-1 for Advanced Melanoma in Older Adults
This trial tests a combination of two drugs—thymosin alpha 1 (an immune-boosting protein) and an anti-PD-1 antibody (a cancer immunotherapy)—in patients 60 and older with advanced melanoma that cannot be surgically removed. The goal is to help the immune system fight the cancer more effectively.
Guangzhou, GuangdongAges 60 years+ - NCT07568405Enrolling by invitation
How Remifentanil Affects Pain Sensitivity During Surgery
This study tests how a pain-relief medication called remifentanil changes the way your body responds to pressure pain. Researchers will measure your pain sensitivity before and after receiving this medication to better understand how it works.
Brussels, Brussels CapitalAges 18–65 - NCT07499128Enrolling by invitation
Continuous temperature monitoring for cytokine release syndrome
This study tests a wearable device that continuously monitors your body temperature to detect cytokine release syndrome, a possible side effect of certain immunotherapies. The goal is to catch it early so you can get treatment faster.
Bethesda, MarylandAges 18–120 - NCT06398860Enrolling by invitation
Safety method trial for 24-hour care staff
This trial tests a new structured method for combining workplace safety and patient safety in 24-hour care settings. It may help if you work at least half-time in such a workplace.
FalunAges 18–70 - NCT04682145Enrolling by invitation
Uses EUHASS data to study turoctocog alfa pegol side effects
This study collects and reviews side-effect information from the EUHASS registry in people with hemophilia. It may help doctors better understand how turoctocog alfa pegol (a clotting medicine) is tolerated in real-world care.
SøborgAges Any age - NCT03690336Enrolling by invitation
Using registry records to study nonacog beta pegol safety
This study looks at safety information using existing patient registry records, not new treatment visits. It may help researchers better understand side effects of nonacog beta pegol by using real-world data.
BaarnAges Any age - NCT06192082Recruiting
Heart risks during painless stomach scope in frail elderly
This study looks at whether older, frail patients have heart problems during a painless stomach scope (gastroscopy). It aims to find safer ways to give sedation for these patients.
Beijing, Beijing MunicipalityAges 65–100 - NCT06575530RecruitingPhase 4
Remimazolam for sedation after non-cardiac surgery
This trial tests a sedative called remimazolam besylate in patients who need a breathing tube and light sedation after non-cardiac surgery. The goal is to see if it works well and is safe.
Beijing, Beijing MunicipalityAges 18–64 - NCT07448038RecruitingPhase 2
Study of selnoflast for heart artery inflammation
This trial tests a drug called selnoflast to see if it can reduce inflammation in the arteries of people with atherosclerosis (hardening of the arteries) who are at risk for heart attacks or other serious heart problems.
Beverly Hills, CaliforniaAges 18–80 - NCT07634666Recruiting
Heart Safety Monitoring During Urologic Cancer Surgery
This study tracks heart health before and after major surgery for prostate or kidney cancer in older adults. Researchers want to predict which patients might experience heart problems after surgery so they can provide better care.
SeoulAges 60 years+ - NCT03720613Recruiting
Testing medicines to prevent heart events in opioid constipation
This study looks at how well naldemedine (and certain other constipation medicines) lower the risk of major heart problems in people who take opioids for constipation. It compares medicine use patterns in people with opioid-induced constipation to see who has fewer serious heart events.
Wilmington, DelawareAges 18 years+ - NCT04691037Recruiting
CT heart scan to guide care for stable chest pain
This trial studies whether a CT heart scan (CCTA) can better guide treatment decisions for people with stable chest pain caused by blocked heart arteries. It may help your care team choose the next best step based on scan results.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05084196RecruitingPhase 3
Melatonin to help prevent kidney damage from vancomycin
This Phase 3 study tests whether melatonin can help protect the kidneys in people who are starting or continuing vancomycin, an antibiotic that can sometimes affect kidney function. If you qualify, you would take melatonin as an added prevention step while you’re on vancomycin.
New Brunswick, New JerseyAges 18–75 - NCT05378035Recruiting
DOAC interruption study for Chinese people with atrial fibrillation
This trial studies how safely and effectively to pause a blood thinner (a DOAC) for about 48 hours before an elective procedure in people with atrial fibrillation. It may help confirm the best way to reduce bleeding risk without raising stroke risk.
Hong KongAges 18–80 - NCT05512169Recruiting
Genetic study in Indian children with newly diagnosed leukemia
This study looks at genetic (DNA) differences to understand acute lymphoblastic leukemia (ALL) in Indian children and how treatments may fit better. You may be able to join if your child is newly diagnosed, meets the study’s treatment plan rules, and provides consent.
New DelhiAges 1–18 - NCT05578300Recruiting
Translating thrombectomy care into real-world practice in Asia-Pacific
This study aims to help endovascular thrombectomy for certain severe strokes work well in everyday hospital care across Asia-Pacific. You may be considered if you’re an adult with a specific type of stroke blocked in a major brain blood vessel.
Linyi, ShandongAges 18 years+
Hear when a new Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adverse event?
- Yes. Clin2 currently lists 191 recruiting adverse event studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adverse event trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adverse event trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.